Crystal Korff, Michele Adaway, Emily G Atkinson, Daniel J Horan, Angela Klunk, Brandy Suarez Silva, Teresita Bellido, Lilian I Plotkin, Alexander G Robling, Joseph P Bidwell
Severe osteoporosis is often treated with one of three Food and Drug Administration (FDA)-approved osteoanabolics. These drugs act by (1) parathyroid hormone (PTH) receptor stimulation using analogues to PTH (teriparatide) or PTH-related peptide (abaloparatide) or by (2) monoclonal antibody neutralization of sclerostin, an innate Wnt inhibitor (Scl-mAb, romosozumab-aqqg). The efficacies of both strategies wane over time. The transcription factor Nmp4 (Nuclear Matrix Protein 4) is expressed in all tissues yet mice lacking this gene are healthy and exhibit enhanced PTH-induced bone formation...
September 1, 2023: Bone